Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study

  • Biotherapy. 1993;6(1):9-12. doi: 10.1007/BF01877380.
P Dufour  1 ,  J M Lang ,  C Giron ,  B Duclos ,  P Haehnel ,  D Jaeck ,  J M Jung ,  F Oberling
Affiliations
  • 1. Service Onco-Hématologie, CHU de Hautepierre, Strasbourg, France.
PMID: 8389572 DOI: 10.1007/BF01877380
Abstract

Sixty-four patients with non metastatic high risk Breast Cancer were randomized in a double blind trial of Adjuvant immunotherapy with sodium dithiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then Adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and 12 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk Breast Cancer subgroup.

Products